Stereotactic Body RadioTherapy With Continuous Tracking for Primary and Secondary Renal Cancer
NCT07285538
Summary
This is a prospective, interventional, monocentric, clinical study of Stereotactic Body Radiation Therapy (SBRT) for primary or secondary renal tumors, delivering from 25-26 Gy/1 fraction to 42-48 Gy/3-4 fractions or 40-50 Gy/5 fractions (standard prescriptions for the internationl guidelines, according to tumor size), using a robotic accelerator -CyberKnife® (Accuray, Sunnyvale, CA)-, with fiducial-tracking, to observe the acute and late toxicity reduction (as primary objectives), due to the maximum precision of the treatment. Secondary objectives are Local Relpase-Free Survival (LRFS), Regional Relapse-Free Survival (RRFS), Distant Metastasis-Free Survival (DMFS), Disease-Free Survival (DFS), Cancer Specific Survival (CSS), Overall Survival (OS) and Quality-of-Life (QoL). A total of 60 participants are expected to be enrolled over four years, and the follow-up of enrolled patients will be three years.
Eligibility
Inclusion Criteria: 1. Histological or clinical diagnosis of primary or secondary kidney tumors 2. Patients aged ≥18 years 3. Signed informed consent 4. Tumor up to 10 cm in the greatest diameter (sum of diameters in case of multiple lesions) 5. PS (ECOG) ≤2 6. No prior local radiotherapy 7. Fertile women using contraception methods previously initiated (a pregnancy test will be prescribed) Exclusion Criteria: 1. Patients aged \< 18 years 2. Tumors \> 10 cm 3. PS ECOG ≥3 4. Psychiatric or other disorders that may prevent the patient from signing informed consent 5. Previous invasive cancer, except for skin cancer (excluding melanoma) unless the patient has been disease-free for at least 3 years (e.g., carcinoma in situ of the oral cavity or bladder) 6. Pregnant women 7. Collagen diseases 8. Sjogren's syndrome
Conditions4
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07285538